Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA, IGNITE Network
JACC Cardiovasc Interv. 2018 11 (2): 181-191

PMID: 29102571 · PMCID: PMC5775044 · DOI:10.1016/j.jcin.2017.07.022

MeSH Terms (23)

Aged Clinical Decision-Making Clopidogrel Cytochrome P-450 CYP2C19 Drug Resistance Female Humans Male Middle Aged Patient Selection Percutaneous Coronary Intervention Pharmacogenetics Pharmacogenomic Testing Pharmacogenomic Variants Platelet Aggregation Inhibitors Prasugrel Hydrochloride Predictive Value of Tests Risk Assessment Risk Factors Ticagrelor Time Factors Treatment Outcome United States

Connections (1)

This publication is referenced by other Labnodes entities:

Links